UNSPSC 51341801: Darunavir

This classification denotes a protease inhibitor with the molecular formula C27H37N3O7S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier YO603Y8113, chemically known as n-((1s,2r)-3-(((4-aminophenyl)sulfonyl)(2-methylpropyl)amino)-2-hydroxy-1-benzylpropyl)((1s,2r,5r)-4,6-dioxabicyclo(3.3.0)oct-2-yloxy)carboxamide but generally known as darunavir, which bears US NIH Compound Identifier 213039. European Medicines Agency schedules Darunavir in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB25394.

UNSPSC 51341801 Darunavir, a Commodity code, nominally names a single antiretroviral pharmaceutical product, but the recent state and local opportunities tagged under this code show little activity directly aligned with darunavir procurement. Instead, the code appears in a completed pharmaceutical warehouse piggyback award and a naloxone-procurement solicitation, neither of which involves darunavir supply. State and local health departments and county health authorities use this code tier to procure pharmaceuticals through competitive bidding and cooperative purchasing vehicles such as MMCAP Infuse consortiums, but the specific products being acquired under recent postings diverge from the code's nominal scope. When darunavir or other antiretroviral drugs are procured by state and local health agencies, they typically flow through warehouse piggyback contracts or direct IFB processes to licensed pharmaceutical distributors, with contract terms of 12 to 36 months and pricing tied to volume and product expiration windows.

The Illinois Department of Public Health and Seminole County, Florida are the issuing bodies in the recent record; both are state health authorities and county health systems using competitive sealed-bid or IFB processes. The Illinois award to Chartwell Rx LLC, closed on August 28, 2026, was a $2,999,999.11 piggyback contract for doxycycline and ciprofloxacin over 12 months plus two renewal years through the MMCAP Infuse consortium. Seminole County's open IFB 60459723LAS, posted June 30, 2026 with a July 26 response deadline, sought 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida. Both solicitations required delivery cost inclusion, drug-free workplace certification, and E-Verify compliance. The code shows minimal recent activity and a mismatch between its nominal product scope and actual procurement; firms evaluating this code should verify whether targeted opportunities are tagged correctly or whether darunavir demand flows through parent-level pharmaceutical codes or state-specific drug procurement initiatives.